This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/curevac-stock-mrna-covid-vaccine-51634041343
- Order Reprints
- Print Article
CureVac stock fell 14.5% in premarket trading.
Guillaume Souvant/AFP via Getty Images
CureVac said early Tuesday it was halting development of its first messenger RNA-based Covid-19 vaccine, and would instead focus on the RNA-based Covid-19 vaccine it is developing with GlaxoSmithKline.
Shares of CureVac (ticker: CVAC) dived 14.5% in premarket trading.
The end of the road for the first CureVac mRNA vaccine, which it calls CVnCoV,…
